Form 8-K - Current report:
SEC Accession No. 0001564590-22-006493
Filing Date
2022-02-24
Accepted
2022-02-24 07:03:20
Documents
12
Period of Report
2022-02-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-8k_20220222.htm   iXBRL 8-K 32520
  Complete submission text file 0001564590-22-006493.txt   164238

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sndx-20220222.xsd EX-101.SCH 5685
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20220222_lab.xml EX-101.LAB 20187
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20220222_pre.xml EX-101.PRE 12035
6 EXTRACTED XBRL INSTANCE DOCUMENT sndx-8k_20220222_htm.xml XML 3663
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 22666474
SIC: 2834 Pharmaceutical Preparations